MSB 3.21% $1.13 mesoblast limited

Ann: Remestemcel-L Improves Survival in High-Risk Acute GvHD, page-90

  1. 216 Posts.
    lightbulb Created with Sketch. 42
    I disagree MSB cash sufficient for next 12 months and Novratis will partner soon. Happy to be long and buying more under $2.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.